Vontobel Holding
TRVI icon

Vontobel Holding’s Trevi Therapeutics TRVI Stock Holding History

Vontobel Holding’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Sell
10,415
-349
-3% -$3.91K ﹤0.01% 1136
2025
Q4 		$135K Sell
10,764
-11,095
-51% -$128K ﹤0.01% 1340
2025
Q3 		$200K Sell
21,859
-3,041
-12% -$22.8K ﹤0.01% 1233
2025
Q2 		$136K Sell
24,900
-6,459
-21% -$40.2K ﹤0.01% 1200
2025
Q1 		$197K Buy
+31,359
New +$150K ﹤0.01% 1015

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vontobel Holding's TRVI Position: Q1 2026 in Review

Vontobel Holding reduced its Trevi Therapeutics (TRVI) stake by 3.2% in Q1 2026, selling an estimated $3.91K and leaving 10,415 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

Vontobel Holding first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. The position peaked at $200K in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Vontobel Holding held 10,415 shares of Trevi Therapeutics worth $124K as of Q1 2026.
  • Vontobel Holding sold 349 Trevi Therapeutics shares in Q1 2026, an estimated $3.91K.
  • Trevi Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #1136 holding.
  • Vontobel Holding first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Vontobel Holding's Trevi Therapeutics position peaked at $200K in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.